All In Biotech

Drug Trial Radar · NCT05515393

A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke

A Multicenter, Randomized, Double-blind, Placebo-parallel Controlled, Dose-exploration Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke

Last checked: Nov 19, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

420

Planned (sponsor's estimate)

Start

Sep 24, 2022

Primary completion

Dec 30, 2023

Study completion Dec 30, 2023

Sponsor

Sponsor type
Industry
Collaborators
First Affiliated Hospital, Sun Yat-Sen University
First posted
Aug 25, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Overall Design: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-exploration study. Main outcome: 1.To evaluate the efficacy and safety of XY03-EA tablets in the treatment of acute ischemic stroke.

Conditions

  • Acute Ischemic Stroke

Interventions

  • XY03-EADrug

    The sample size was 420 patients, and 140 patients were treated with XY03-EA 300 mg, 600 mg and placebo respectively. The 300-mg group took two tablets of placebo and two tablets of XY03-EA once, three times a day. The 600-mg group took four tablets of XY03-EA once, three times a day. The placebo group took four tablets of placebo once ,three times a day.

  • XY03-EA PlaceboDrug

    XY03-EA Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients with Modified Rankin Scale (mRS) score ≤ 1 point at 90 days after administration.Time frame: 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shijiazhuang Yiling Pharmaceutical Co.,Ltd

    Shijiazhuang, Hebei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.